Atreca

Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA.

SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives.

Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that, as part of its ongoing efforts to lower operating expenses, the Company has entered into an agreement to terminate its lease agreement pertaining to the Company's headquarters in San Carlos, CA, which represented approximately $13 million of annual expenditures. In addition, Herb Cross, Chief Financial Officer, will depart the Company on September 22, 2023, to pursue an external opportunity. Mr. Cross will continue to support the Company as a consultant through the first quarter of 2024. John Orwin, Chief Executive Officer of the Company, will assume the role of principal financial officer and Rick Ruiz, Vice President, Finance of the Company, will assume the role of principal accounting officer going forward.

Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross

Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.

Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%

Suspending development of ATRC-101 Cost-saving measures include 40% workforce reduction Focusing on advancing earlier stage ADC candidates and preserving discovery capabilities SAN CARLOS, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2023, and announced a corporate reorganization to reduce expenses and extend its cash runway.

Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring

Precision Biosciences

Tech companies in certain high-growth sectors like semiconductors, AI, and cloud predominantly drove this year's bull market. But while these giants made headlines, many penny stocks continued trading at bargain prices.

3 Penny Stocks to Catapult You Into the Millionaires' Club

Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high target expression; ATRC-101 continues to be well-tolerated

Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting

SAN CARLOS, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2023 and provided an overview of recent developments.

Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that data from the Phase 1b study of ATRC-101 will be presented during an oral abstract session at the American Society of Clinical Oncology 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois.

Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting

SAN CARLOS, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that John A. Orwin, President and Chief Executive Officer, will be participating in a panel discussion on T-Cells and “Informative B-Cells” at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20th, 2023, from 10:00 to 10:45 AM ET.

Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Atreca, Inc. (BCEL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Atreca, Inc. (BCEL) Is a Great 'Buy the Bottom' Stock Now

Atreca, Inc. (NASDAQ:BCEL ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Alex Gray - Head of Investor Relations John Orwin - CEO Tito Serafini - Chief Strategy Officer and Founder Philippe Bishop - Chief Medical Officer Stephen Gould - Chief Scientific Officer Herb Cross - Chief Financial Officer Conference Call Participants Divya Rao - Cowen Roger Song - Jefferies John Newman - Canaccord Tony Butler - EF Hutton Stephen Willey - Stifel Kemp Dolliver - Brookline Capital Operator Thank you for standing by. Welcome to the Atreca's Fourth Quarter and Year End 2022 Earnings Call.

Atreca, Inc. (BCEL) Q4 2022 Earnings Call Transcript

ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression

Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101 Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101

Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023

SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that John A. Orwin, President and Chief Executive Officer, will be participating in a panel discussion focused on novel oncology targets at Cowen's 43rd Annual Health Care Conference on March 7, 2023, from 9:10 to 10:20 AM EST.

Atreca to Participate at Cowen's 43rd Annual Health Care Conference

Atreca (NASDAQ: BCEL ) stock is getting a boost on Tuesday as the company continues a recent rally connected to insider buying. On Monday, shares of BCEL stock jumped nearly 14% after a series of filings with the U.S. Securities and Exchange Commission (SEC).

Why Is Atreca (BCEL) Stock Up Today?

SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced, as part of their existing strategic collaboration, they have mutually selected the first program combining an Atreca-discovered antibody with Xencor's XmAb® bispecific Fc domain and a cytotoxic T-cell binding domain (CD3).

Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target

BCEL is set to produce additional data from a phase 1b trial of its antibody ATRC-101 in multiple solid tumor types. Based on previous data, BCEL has refined the patients it enrolls in the trial, which could improve the strength of the results it produces.

Atreca Locks In A Catalyst In The Oncology Space

SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately.

Atreca Appoints Philippe Bishop, MD as Chief Medical Officer

SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments.

Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming conferences:

Atreca to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two poster presentations at the SITC 2022 Annual Meeting, being held November 8-12 in Boston, Massachusetts.

Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2022 and provided an overview of recent developments.

Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #AI--Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Stephen Gould, Ph.D., as Chief Scientific Officer.

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Company continuing to advance ATRC-101, ATRC-301 and other oncology pipeline assets

News for Atreca Stock (BCEL)